About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Researchers Identify a Rescuer for Vital Tumor-Suppressor

by Bidita Debnath on November 30, 2013 at 3:51 PM
Font : A-A+

 Researchers Identify a Rescuer for Vital Tumor-Suppressor

At The University of Texas MD Anderson Cancer Center, a protector for PTEN, a tumor-thwarting protein often missing in cancer cells, has emerged from research published online at Nature Cell Biology this week.

"We discovered that the enzyme USP13 stabilizes the PTEN protein by reversing a process that marks various proteins for destruction by the cell's proteasome," said the paper's senior author Li Ma, Ph.D., assistant professor of Experimental Radiation Oncology.

Advertisement

"USP13 also suppresses tumor formation and glycolysis though PTEN," Ma said. Glycolysis is a glucose metabolism pathway that tumors rely on to thrive and grow.

After establishing the relationship in cell lines and mouse model experiments, the team found low levels of USP13 in human breast tumors correlate with lower levels of PTEN. Both proteins were more abundantly present in normal breast tissue.
Advertisement

PTEN regulates cell growth and division. It also inhibits signaling by the AKT molecular pathway, which is involved in cell survival, metabolism and growth and is often overactive in human cancers.

This discovery provides a new way to think about PTEN deficiency and how it might be remedied. Ma noted the likely keys to possible treatment would be identifying druggable oncogenes that suppress USP13 in cancer cells, or hitting targets usually controlled by PTEN.

"In our paper, we showed that loss of USP13 leads to loss of PTEN and activation of AKT signaling, and that treatment of a breast cancer cell line with the AKT inhibitor MK-2206 can abolish the effect of USP13 loss on promoting tumor cell proliferation," Ma said. MK-2206 is actively being tested in clinical trials against a variety of cancers at MD Anderson and elsewhere, including advanced breast cancer.

Genetic defects alone don't explain PTEN's absence

"The rationale of our work is that despite the frequent genetic alterations seen in the PTEN gene in human cancer, loss of the PTEN protein has been observed in a much higher percentage of human tumors," Ma said. "For example, approximately 5 percent of non-inherited breast tumors carry PTEN gene mutations, but loss of the PTEN protein is actually reported in nearly 40 percent of breast tumors."

This suggested, Ma said, that regulation of PTEN after gene expression or after its translation into a protein "may contribute substantially to development of human breast cancer."

Ma and colleagues focused on ubiquitylation, a process that regulates proteins by attaching molecules called ubiquitins to them. When more than one ubiquitin is attached to a protein, a chain forms that is both a target and a handle for the proteasome - a protein complex that degrades proteins and recycles bits of them for other use.

Previous studies had revealed several proteins that attach ubiquitins to PTEN to initiate its destruction. Nothing had been identified that reverses that process for PTEN.

Auditioning 30 DUBs to find one PTEN defender

The team screened 30 known deubiquitylating enzymes (DUBs). Of those, USP13 was noteworthy for its ability to stabilize PTEN by directly binding to it and removing ubiquitins. A series of experiments showed that overexpressing USP13 in breast cancer cells:

  • Increased PTEN expression and decreased cell multiplication and conversion to a cancerous state.
  • Reduced cancer-promoting AKT signaling.
  • Had no effect in cancer cells that lacked the PTEN gene.

The team also confirmed that USP13 removes ubiquitins from PTEN. Silencing USP13 expression tripled the polyubiquitylation of PTEN, expressing USP13 reduced it by 65 percent.

Knocking down USP13 in breast cancer cells increased cell multiplication and growth, while restoring either PTEN or USP13 completely reversed the effect.

Lower USP13, larger tumors in mice

In mice, those implanted with a breast cancer cell line with USP13 depleted had a 2.5-fold increase in tumor volume and a 3.5-fold increase in tumor weight over 65 days compared with a control group.

Ma and colleagues also analyzed USP13 and PTEN using human breast cancer progression tissue microarrays from the National Cancer Institute.

  • Lower PTEN levels were found in 152 of 206 tumors (73.8 percent) and lower USP13 levels in 83 of 201 (41.3 percent).
  • Of the 83 tumors with low USP13, 73 (88 percent) also had low PTEN.
  • In normal breast tissue, only 31.8 percent had low levels of PTEN; 13.2 percent had low USP13.

"Our future studies aim to determine the physiological function of USP13 and how USP13 expression is lost in human cancer," Ma said.

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Latest Research News

Frozen Frontier: Humans Leave a Unique Microbial Mark on Mount Everest
Located at the South Col, the rocky area between Mount Everest and Lhotse serves as the final campsite for climbers as well as a frozen legacy of hardy microbes.
How Does Protein Synthesis in Diarrhea Causing Parasite Work?
The new finding is found to be valuable for screening specific medications and treatment against Giardia and other protozoan parasites.
Unlocking the Potential of CRISPR for Reversing Vision Loss
New CRISPR genome-editing strategy was found to have a positive impact in the treatment of inherited retinal diseases such as retinitis pigmentosa.
 New RT-qPCR Kit Detects Influenza, COVID-19
H3N2 Influenza: The newly developed RT-qPCR Kit to identify influenza, COVID-19 and respiratory virus has got approval from ICMR.
 Rheumatoid Arthritis: Does Taking Sex Hormones Help Women?
Does hormone replacement therapy help rheumatoid arthritis? Yes, the use of exogenous sex hormones is associated with remission in perimenopausal female patients.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Researchers Identify a Rescuer for Vital Tumor-Suppressor Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests